Clinical trials: Cryptogenic Stroke
Atrial Fibrillation, Ischemic Stroke
Mobile Phones in Cryptogenic Stroke Patients Bringing Single Lead ECGs to Detect Atrial Fibrillation
The main objective of this study is to compare the incidence of detected atrial fibrillation (AF) in cryptogenic stroke patients by a single lead ECG device with the incidence of detected AF by a 7-Day Holter ECG.
- Conditions
- Atrial Fibrillation, Ischemic Stroke, Transient Ischemic Attack
- Trial name
- MOBILE-AF (NCT02507986)
- Testing
- Single lead ECG device, 7-Day Holter monitor.
- Where
- 7 sites in Denmark, Netherlands
- Volunteers
- 57 people
- Sponsor
- Leiden University
Atrial Fibrillation, Stroke
Extended Rhythm SCreening for AtRial Fibrillation in Cryptogenic Stroke Patients
Recent studies demonstrated that prolonged rhythm observation increases the detection of atrial fibrillation in patients prior diagnosed as cryptogenic stroke.
- Trial name
- SCARF (NCT01550042)
- Where
- Netherlands
- Volunteers
- 4 people
- Sponsor
- Medisch Spectrum Twente
Atrial Fibrillation, Stroke
"Cryptogenic Stroke and Atrial Fibrillation Detection Through Implantable Loop Recorder (ILR)"
STUDY TYPE: Prospective, national , multicenter, and observational study. OBJECTIVE: To assess the incidence of AF in patients with cryptogenic stroke who have implanted an AF detection device during a period of 2 years.
- Trial name
- CRYPTONITE (NCT01025947)
- Where
- 2 sites in Spain
- Volunteers
- 100 people
- Sponsor
- University of Valencia
Cerebrovascular Stroke, Atrial Fibrillation
Prediction and Detection of Occult Atrial Fibrillation in Patients After Acute Cryptogenic Stroke and TIA
PROACTIA is a prospective, event-driven observational study. It aims to propose a composite scoring system in order to evaluate the risk of paroxysmal atrial fibrillation (PAF) in patients after acute cryptogenic stroke and…
- Trial name
- PROACTIA (NCT02725944)
- Testing
- Implantation of ICRM
- Where
- Norway
- Volunteers
- 251 people
- Sponsor
- University Hospital, Akershus
Cryptogenic Stroke, Atrial Fibrillation
Stroke of Unknown Cause in Women: The Impact of Long-term Heart Monitoring on Stroke Recurrence
The goal of this observational study is to investigate sex - differences in detection rate of atrial fibrillation after cryptogenic stroke (embolic stroke of unknown cause) - using an implantable cardiac rhythm monitor - and the…
- Conditions
- Cryptogenic Stroke, Atrial Fibrillation, Implantable Cardiac Monitor, Secondary Stroke Prevention
- Trial name
- STROKEWISE (NCT07194811)
- Where
- Norway
- Volunteers
- 1,400 people
- Sponsor
- University Hospital, Akershus
Patent Foramen Ovale
PFx Closure System in Subjects With Cryptogenic Stroke,Transient Ischemic Attack,Migraine or Decompression Illness(PFO)
The primary objective of this study is to demonstrate the safety and performance of the PFx Closure System when utilized for patients with PFOs suffering from cryptogenic stroke, transient ischemic attack, migraine or…
- Trial name
- NCT00335296
- Testing
- PFx catheter
- Where
- 4 sites in Belgium, France and 1 more
- Volunteers
- 100 people
- Sponsor
- Cierra
Ischemic Stroke, Ischemia
Biomarkers of Acute Stroke in Clinic
The proposed study will investigate the clinical use of the ISCDX test that may differentiate between diverse stroke etiologies as listed below: Aim 1: Differentiate between cardioembolic and large artery atherosclerotic ischemic…
- Conditions
- Ischemic Stroke, Ischemia, Atrial Fibrillation, Transient Ischemic Attack
- Trial name
- BASIC (NCT03897478)
- Testing
- ISCDX blood test
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Ischemia Care LLC
Cryptogenic Stroke, Atrial Fibrillation
Improving AF Detection in Cryptogenic Stroke
No cause for stroke is found in up to 30% of cases despite extensive investigations. These are called cryptogenic strokes (CS). 1 in 4 stroke survivors will suffer another in 5 years and this is a leading cause of fear and…
- Trial name
- CSAF-AW (NCT05007847)
- Testing
- Apple Watch-based heart rhythm monitoring
- Where
- 4 sites in United Kingdom
- Volunteers
- 27 people
- Sponsor
- Barts & The London NHS Trust
Stroke, PFO - Patent Foramen Ovale
Japan Post Marketing Surveillance of the GORE® CARDIOFORM Septal Occluder
The purpose of this post-marketing surveillance is to evaluate the effectiveness and safety of GORE® CARDIOFORM Septal Occluder under the post-marketing setting in Japan.
- Conditions
- Stroke, PFO - Patent Foramen Ovale, Cryptogenic Stroke, TIA
- Trial name
- GSO-PFO PMS (NCT05529901)
- Testing
- GORE® CARDIOFORM Septal Occluder
- Where
- Japan
- Volunteers
- 300 people
- Sponsor
- W.L.Gore & Associates
Paroxysmal Atrial Fibrillation, Cryptogenic Stroke
Smartwatch and External Holter Monitoring to Detect Atrial Fibrillation in Patients With Cryptogenic Stroke
Stroke recurrence largely depends on the detection of the cause and the control of vascular risk factors, with occult atrial fibrillation (AF) being one of the most important.
- Trial name
- SMARTTHUNDER (NCT05565781)
- Testing
- ECG smartwatch, Insertable Cardiac Monitor (ICM), External ECG Monitoring
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Tachyarrhythmia, Atrial Fibrillation (AF)
Master Study of the BIOMONITOR III and Incision and Insertion Tool (FIT OneStep)
This study is a post-market clinical follow-up (PMCF) study to identify and evaluate residual risks associated with the use of the BIOMONITOR III and BIOMONITOR IIIm that are discovered or remain even after risk analysis, risk…
- Conditions
- Tachyarrhythmia, Atrial Fibrillation (AF), Syncope, Cryptogenic Stroke
- Trial name
- NCT04025710
- Testing
- BIOMONITOR III and BIOMONITOR IIIm
- Where
- 27 sites in Australia, Austria and 4 more
- Volunteers
- 167 people
- Sponsor
- Biotronik SE & Co. KG
Stroke, Stroke, Ischemic
MLC1501 Study Assessing Efficacy in STROke Recovery
This is a multi-center, randomized, double-blind, placebo-controlled, dose-response study of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 low-dose twice a…
- Conditions
- Stroke, Stroke, Ischemic, Strokes Thrombotic, Stroke Sequelae
- Trial name
- MAEStro (NCT05046106)
- Testing
- MLC1501
- Volunteers
- 540 people
- Sponsor
- Moleac Pte Ltd.
Ischemic Stroke, Atrial Fibrillation
Ischemia Care Biomarkers of Acute Stroke Etiology (BASE)
The proposed study will validate the clinical use of new biomarker blood tests to identify blood components that may differentiate between diverse stroke etiologies and clinical outcomes as listed below: 1.
- Conditions
- Ischemic Stroke, Atrial Fibrillation, Transient Ischemic Attacks, Transient Cerebrovascular Events
- Trial name
- BASE (NCT02014896)
- Testing
- Biomarker blood draw
- Where
- 22 sites in United States
- Volunteers
- 1,750 people
- Sponsor
- Ischemia Care LLC
Patent Foramen Ovale, Stroke
PFO ACCESS Registry
Closure of Patent Foramen Ovale with the AMPLATZER® PFO OCCLUDER in patients with at least two cryptogenic strokes due to presumed paradoxical embolism through a patent foramen ovale and who have failed conventional therapy.
- Trial name
- NCT00583401
- Testing
- Device closure with the AMPLATZER PFO Occluder
- Sponsor
- Abbott Medical Devices
Hydrocephalus, Hydrocephalus in Children
Post Market Clinical Follow-up of CODMAN CERTAS Programmable Valve
Post-Market Clinical Follow-up Registry of Patients with CODMAN CERTAS Plus Programmable Valves.
- Conditions
- Hydrocephalus, Hydrocephalus in Children, NPH (Normal Pressure Hydrocephalus), IIH - Idiopathic Intracranial Hypertension
- Trial name
- NCT05397106
- Testing
- CODMAN CERTAS Plus Programmable Valve
- Where
- 9 sites in Belgium, Germany and 2 more
- Volunteers
- 160 people
- Sponsor
- Integra LifeSciences Corporation
Cryptogenic Ischemic Stroke, Patent Foramen Ovale
PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years
To assess whether PFO closure plus antiplatelet therapy is superior to antiplatelet therapy alone and whether oral anticoagulant therapy is superior to antiplatelet therapy to prevent stroke recurrence in patients aged 60 to 80…
- Trial name
- CLOSE-2 (NCT05387954)
- Testing
- Transcatheter PFO closure, Oral Anticoagulant, Direct-Acting, Antiplatelet therapy
- Where
- 42 sites in France
- Volunteers
- 792 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cryptogenic Stroke, Atrial Fibrillation
Atrial Imaging and Cardiac Rhythm In Embolic Stroke
The ARIES study is an observational study in which patients with a recent acute ischemic stroke of cryptogenic aetiology are consecutively enrolled in order to perform a extensive cardiologic work-up.
- Conditions
- Cryptogenic Stroke, Atrial Fibrillation, Atrial Dilatation, Stroke, Ischemic
- Trial name
- ARIES (NCT05486221)
- Testing
- Extensive cardiologic work-up
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Cryptogenic Symptomatic Transient Ischemic Attack, Cryptogenic Ischemic Stroke
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
The 2006 American Heart Association / American Stroke Association Council on Stroke Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic recommended that patients with cryptogenic stroke take…
- Trial name
- CRYSTAL-AF (NCT00924638)
- Testing
- Reveal® XT Insertable Cardiac Monitor
- Where
- 55 sites in United States, Austria and 12 more
- Volunteers
- 447 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Cryptogenic Stroke
Cardiac Abnormalities in Stroke Prevention and Risk of Recurrence
This is a multi-center retrospective analysis of consecutive adult patients with cryptogenic stroke patients following a comprehensive workup for the underlying stroke etiology.
- Trial name
- CASPR (NCT06398366)
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- The Cooper Health System
Patent Foramen Ovale, Ischemic Stroke
Discontinuation of Antithrombotic Treatment Following Patent Foramen Ovale Closure in Young Patients With Cryptogenic Stroke
To determine the safety of antithrombotic treatment discontinuation 12 months following successful transcatheter PFO closure.
- Conditions
- Patent Foramen Ovale, Ischemic Stroke, Bleeding Ulcer
- Trial name
- HALTI (NCT04475510)
- Testing
- Antiplatelet treatment discontinuation
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Josep Rodes-Cabau